Academician
TUBA HACIBEKİROĞLU
PROFESÖR
SAKARYA ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Hematoloji (İç Hastalıkları)
A quick look at recorded outputs — details below.
- Articles 85
- Projects 0
- Books 2
- Proceedings 75
- Patents 0
- Artistic 0
Scopus (SJR)
Q1
10
Q2
23
Q3
32
Q4
9
WoS (JCR)
Q1
5
Q2
5
Q3
23
Q4
38
TR Index
18
articles
Field+year+type normalized OpenAlex percentiles — not Clarivate ESI / SciVal.
Top 1% articles
1
Top 10% articles
4
Avg percentile
70.1%
Top 1% share
9.1%
Top 10% share
36.4%
Articles
Articles with YÖKSİS and OpenAlex source split; narrow by quartile or TR Index.
Article list
- 2023 The Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients With LowRisk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 3.0%
- 2023 Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. YÖKSİS SJR Q1 JCR Q1
- 2023 Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. YÖKSİS SJR Q3 JCR Q3
- 2021 Does Total Body Irradiation Have a Favorable Impact on Thrombocyte Engraftment as per Neutrophil Engraftment in Allogeneic Stem Cell Transplantation? YÖKSİS JCR Q3
- 2021 Convalescent plasma therapy in patients with COVID-19 YÖKSİS SJR Q3 JCR Q4 OpenAlex top 10% OpenAlex 90.7%
- 2021 Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients YÖKSİS SJR Q3 JCR Q4
- 2021 DEMONSTRATION OF SARS-COV-2 IN BONE MARROW CELLS AND CHANGES IN THE HEMATOPOIETIC CELL LINES YÖKSİS SJR Q4 JCR Q4
- 2021 Covid-19 clinical course and blood groups: Turkish population-based study YÖKSİS TR Index SJR Q3 JCR Q3
- 2021 Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey YÖKSİS SJR Q3 JCR Q4
- 2021 THE REAL WORLD EXPERIENCE WITH SINGLE AGENT IBRUTINIB IN RELAPSED/REFRACTORY CLL YÖKSİS SJR Q2 JCR Q3
- 2021 Covid-19 clinical course and blood groups: Turkish population-based study YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 81.6%
- 2021 Acute tubulointerstitial nephritis after COVID-19 m-RNA BNT162b2 vaccine YÖKSİS SJR Q2
- 2021 The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL YÖKSİS SJR Q2 JCR Q3 OpenAlex top 1% OpenAlex 99.9%
- 2021 The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL YÖKSİS SJR Q2 JCR Q3
- 2021 Covid-19 clinical course and blood groups: Turkish population-based study YÖKSİS TR Index SJR Q3 JCR Q3
- 2021 Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers YÖKSİS SJR Q1 JCR Q2
- 2021 Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock YÖKSİS SJR Q2 JCR Q4
- 2021 Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock YÖKSİS SJR Q2 JCR Q4
- 2021 Efficacy of convalescent plasma according to blood groups in COVID-19 patients YÖKSİS TR Index SJR Q3 JCR Q3
- 2021 An Experience on Pomalidomide in Patients within Relapsed/Refractory Multiple Myeloma - A Multicenter Study in Turkey YÖKSİS